Bone Health and Linear Growth in Children With Familial Hypoparathyroidism Treated With Human Parathyroid Hormone 1-34
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf065 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Karen K Winer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD 20892-7002…. Hauptthemen laut MEDLINE: Bone Density, Hypoparathyroidism, Parathyroid Hormone, Bone Development. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAID, NICHD.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Context
Our study explores the impact of human parathyroid hormone (PTH) 1-34 injections (PTH therapy) on growth, areal bone mineral density (BMD), and bone quality (measured by trabecular bone score, TBS) in hypoparathyroidism due to autoimmune polyendocrine syndrome type 1 (APS-1) or an activating variant of the calcium sensing receptor (CaR).
Objective
To assess associations of (1) age and PTH therapy duration with age-standardized Z-scores for height (HAZ), BMD (BMD-Z), and TBS (TBS-Z) in CaR or APS-1, and (2) APS-1 disease severity with BMD-Z and TBS-Z.
Methods
This secondary analysis pooled linear growth and lumbar spine (LS) dual-energy x-ray absorptiometry data from studies of hypoparathyroidism with mean baseline age of 13.7 ± 5.5 years. Comparing the 2 diagnostic etiologies (18 APS-1 and 9 CaR), we examined the impact of age and PTH duration on HAZ, LS-BMD-Z, and LS-TBS-Z using longitudinal mixed-effects modeling.
Results
During PTH therapy, mean HAZ remained below 0 in the APS-1 group at all ages, whereas HAZ increased in the CaR group (age by group interaction P < .0001). Mean LS-BMD-Z were normal (BMD-Z: 0 ± 1) for both groups. Mean LS-TBS-Z were near or above 0 and differed by group; CaR showed an upward trajectory according to time on PTH whereas the APS-1 group maintained a LS-TBS-Z of approximately 0 (time by group interaction P = .02). The APS-1 group with greater disease severity (≥7 manifestations) had lower LS-BMD-Z and LS-TBS-Z than the less severe APS-1 or CaR groups.
Conclusion
Our study highlights distinct growth and BMD patterns in APS-1 and CaR and underscores the need for careful monitoring and tailored treatment strategies to optimize growth and bone health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD 20892-7002, USA.
- Laboratory of Clinical Immunology & Microbiology, National Institute of Allergy & Infectious Diseases (NIAID), National Institutes of Health, Bethesda, MD 20892, USA.
- Division of Gastroenterology, Hepatology and Nutrition, The Children's Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
- Division of Endocrinology, The Children's Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
- National Institutes of Health Clinical Center, Radiology and Imaging Sciences, Bethesda, MD 20892, USA.
- Center of Bone Diseases, Bone and Joint Department, Lausanne University Hospital and University of Lausanne, Av. Pierre Decker 4, Lausanne 1011, Switzerland.
ORCID-Profile: Karen K Winer
Förderung
- NHLBI NIH HHS
- NIAID
- NICHD
- NIH
- Division of Intramural Research
Zitieren
APA
Winer, K. K., Zemel, B. S., Kelly, A., Reynolds, J. C., Pechacek, J., Webb, T., Hans, D., Lionakis, M. S., & Kalkwarf, H. J. (2025). Bone Health and Linear Growth in Children With Familial Hypoparathyroidism Treated With Human Parathyroid Hormone 1-34. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf065
Vancouver
Winer KK, Zemel BS, Kelly A, Reynolds JC, Pechacek J, Webb T, et al. Bone Health and Linear Growth in Children With Familial Hypoparathyroidism Treated With Human Parathyroid Hormone 1-34. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf065
BibTeX
@article{Winer2025,
author = {Winer, Karen K and Zemel, Babette S and Kelly, Andrea and Reynolds, James C and Pechacek, Joseph and Webb, Taura and Hans, Didier and Lionakis, Michail S and Kalkwarf, Heidi J},
title = {Bone Health and Linear Growth in Children With Familial Hypoparathyroidism Treated With Human Parathyroid Hormone 1-34},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf065}
}
EUVIMED